Lessons drawn from recent HIV vaccine efficacy trials.
Lessons drawn from recent HIV vaccine efficacy trials.
复制标题
DOI：
10.1097/qai.0b013e3181fbca02
复制
发表时间：
2010-12
期刊：
影响因子：
--
通讯作者：
Buchbinder SP
中科院分区：
文献类型：
--
作者：
Fuchs JD;Sobieszczyk ME;Hammer SM;Buchbinder SP
需要一种安全有效的艾滋病毒疫苗来遏制美国和全球的流行病。然而，尽管进行了25年以上的重点研究，但预防性疫苗的寻找一直难以捉摸。RV144泰国药效试验的结果重新燃起了希望，即疫苗可能防止感染艾滋病毒。我们可以从RV144和其他最近的概念疗效试验中吸取一些科学和可操作的经验教训。在这里，我们描述了试验结果如何，一些意想不到的，突出了这些临床研究在艾滋病毒疫苗发现中所发挥的基本作用。这些试验还告诉我们，数据分析和结果传播的透明度可以产生可观的回报，需要努力让社区参与，特别是那些受疫情影响最严重的社区，以提高研究素养和试行招募。未来的疗效试验设计可能包含新的、部分有效的预防策略。尽管规模和复杂性更大，但这些试验可能为探索与正在研究的疫苗的协同作用提供独特的机会。
A safe and effective HIV vaccine is needed to curtail the US and global epidemics. However, the search for a preventive vaccine has been elusive, despite more than 25 years of focused research. Results from the RV144 Thai efficacy trial have renewed hope that a vaccine may protect against HIV acquisition. We can draw several scientific and operational lessons from RV144 and other recent tests of concept efficacy trials. Here we describe how trial results, some unexpected, highlight the fundamental role these clinical studies play in HIV vaccine discovery. These trials also teach us that transparency in data analysis and results dissemination can yield substantial rewards and that efforts to engage communities, particularly those most heavily affected by the epidemic, are needed to augment research literacy and trial recruitment. Future efficacy trial designs may incorporate novel, partially effective prevention strategies. Although greater in size and complexity, these trials may offer unique opportunities to explore synergies with vaccines under study.